65,437 trials
Glaucoma
Primary: Percentage of Participants Achieving at Least 20% Intraocular Pressure (IOP) Reduction (Improvement) From Baseline at Month 12 With Prespecified Caveats — 62.1; 68.2…
Diabetes Mellitus, Type 1
Primary: HbA1c — -6.1; 0.5 mmol/mol
Surgical Skin Preparation
Primary: Bacterial Reduction - Groin — 4.133; 3.642; 1.277 log 10 CFU/cm2
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs , and TEAEs Leading to Participant Discontinuation From Study — 0; 3; 0; 0…
Osteoarthritis, Knee
Primary: Mean Change From Baseline in WOMAC A (Pain) Dimension — -14.13; -17.16 score on a scale — p=0.0833
Head and Neck Squamous Cell Carcinoma
Primary: Phase I - Dose-Limiting Toxicity — 0; 0 dose-limiting toxicities
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Pertrochanteric Fracture
Primary: Amount (mg) of Narcotics (Oral Morphine mg Equivalents) Used — 16; 10 morphine milligram equivalents (MME)
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 74.0; 1.0 percentage of responders
Prostate Cancer
Primary: Number of Participants With Increased Immune Cell Infiltration Across Arms — 7; 2; 14; 3 Participants
Epistaxis
Primary: Frequency of Epistaxis — -1.68; 1.14 Nosebleeds per week — p=0.16
Carotid Arteries
Primary: Uptake of [F-18] RGD-K5 by Carotid Plaque With PET/MRI Imaging in the Artery Believed to be the Cause of Transient Ischemic Attack (TIA) or Stroke Symptoms Compared to…
SARS-CoV-2 Infection
Primary: Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1) — 4; 5; 9…
Visual Acuity
Primary: Visual Acuity — -0.13; -0.13; -0.04; -0.01 logMAR
Aortic Stenosis · Inflammation · Thrombosis
Primary: Platelet Reactivity — 275.5; 251; 234; 128.5 Platelet Reactivity Units